Market capitalization | $588.71m |
Enterprise Value | $304.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.03 |
P/S ratio (TTM) P/S ratio | 3.92 |
P/B ratio (TTM) P/B ratio | 2.28 |
Revenue growth (TTM) Revenue growth | -42.89% |
Revenue (TTM) Revenue | $150.16m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
11 Analysts have issued a Arcturus Therapeutics Ltd forecast:
11 Analysts have issued a Arcturus Therapeutics Ltd forecast:
Jun '24 |
+/-
%
|
||
Revenue | 150 150 |
43%
43%
|
|
Gross Profit | 147 147 |
-
|
|
EBITDA | -22 -22 |
124%
124%
|
EBIT (Operating Income) EBIT | -25 -25 |
128%
128%
|
Net Profit | -69 -69 |
186%
186%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Head office | Israel |
CEO | Joseph Payne |
Employees | 180 |
Founded | 2013 |
Website | www.arcturusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.